| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C20H19FN4O2S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
GSK583 is a highly potent, orally active, selective inhibitor of RIP2 kinase, with an IC50 of 5 nM. It also inhibits both TNF-α and IL-6 production, with an IC50 of 200 nM. It is supplied as a light yellow to yellow solid (C20H19FN4O2S, MW 398.45) at 99.93% purity.
Physical & Chemical Properties
| CAS Number | 1346547-00-9 |
|---|---|
| Molecular Formula | C20H19FN4O2S |
| Molecular Weight | 398.45 g/mol |
| Purity | 99.93% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | FC1=CC2=C(NN=C2NC3=CC=NC4=CC=C(S(=O)(C(C)(C)C)=O)C=C34)C=C1 |
| Signaling Pathway | Apoptosis |
| Solubility | In Vitro: DMSO: ≥ 100 mg/mL (250.97 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) * "≥" means soluble, but saturation unknown. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 1 year; -20°C, 6 months. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
IC50: 5 nM (RIP2K)[1]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 100 mg/mL (250.97 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 1 year) or -20°C (up to 6 months); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (6.27 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Data provided by the manufacturer.
In Vitro
GSK583 (1 μM) is highly selective across a panel of 300 kinases, which includes p38α and VEGFR2. GSK583 potently inhibits MDP-stimulated tumor necrosis factor-alpha (TNFα) production in a dose-dependent manner, with an IC50 of 8 nM. In a similar MDP-induced TNFα production assay, GSK583 shows only a modest drop in potency in human whole blood (IC50 = 237 nM), as well as in rat whole blood (IC50 = 133 nM)[1].
In Vivo
GSK583 (0.1, 1, and 10 mg/kg, p.o.) dose-dependently inhibits serum KC (the rodent orthologue of IL-8) levels in rats, with an IC50 of 50 nM (or 20 ng/mL) derived from rat blood concentrations. Likewise, GSK583 dose-dependently inhibits serum KC levels and neutrophil recruitment into the peritoneal cavity in mice; the IC50, derived from mouse blood concentration, is 37 nM (15 ng/mL)[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Animal Administration[1]
Mice[1] Use female C57Bl/6 mice for cytokine analyses and male Balb/c mice for peritoneal neutrophil analyses (n=10/treatment group); dose orally with vehicle or GSK583 (0.1, 1, or 10 mg/kg) 15 min before MDP challenge. For peritoneal neutrophil analysis, sacrifice the mice 4 h after MDP challenge (30 μg, i.p.) and collect peritoneal fluid by lavage. Quantify peritoneal neutrophils by FACS analysis. Rats[1] Dose female Crl:CD(SD) rats (n=8/treatment group) orally with vehicle or GSK583 15 min before MDP challenge (150 μg/rat, IV). At 2 h after MDP challenge, sacrifice the rats and prepare terminal serum from blood collected by cardiac stick. Quantify serum cytokine levels (IL-6, IL-8 or KC, IL-1β, and TNFα) on the MSD platform.
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. Nat Commun 2026 Feb 12;17(1):1214. PMID: 41680175
Ripk2 promotes CD8+ T cell inactivation and hepatocellular carcinoma progression through Myb/Cxcl9 and Pax5/Adpgk signaling pathways. Cell Death Dis 2026 May 29. PMID: 42215445
Thlaspi arvense attenuates colitis-associated colorectal tumorigenesis through suppression of neutrophil recruitment via the NOD/NF-κB pathway. Chin Med 2026 Apr 17;21(1):119. PMID: 41998751
NOD2 negatively regulated titanium particle-induced osteolysis in mice. Biomater Sci 2019 Jul 1;7(7):2702-2715.
The kinesin-14 family motor protein KIFC2 promotes prostate cancer progression by regulating p65. J Biol Chem 2023 Nov;299(11):105253. PMID: 37716704
Rip2 Is Required for Nod2-Mediated Lysozyme Sorting in Paneth Cells. J Immunol 2017 May 1;198(9):3729-3736.
Bartonella henselae Persistence within Mesenchymal Stromal Cells Enhances Endothelial Cell Activation and Infectibility That Amplifies the Angiogenic Process. Infect Immun 2021 Jul 15;89(8):e0014121. PMID: 34031126
RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway. PLoS One 2026 Jan 21;21(1):e0341445. PMID: 41563982
Research Square Preprint. 2020 Dec.
